13:30 - 13:45 Opening & Welcome

13:45 - 14:30 Opening keynote

• B Huntly (United Kingdom)

14:30 - 16:00 Session 1: Precision medicine trials

Chair: K Flaherty (United States)

• EXALT1 and 2 trials
  P Staber (Austria)
• MATCH trial
  K Flaherty (United States)
• EVIDENT trial
  K Kryeziu (Norway)

16:00 - 16:30 Coffee break

16:30 - 17:00 Session 2: Poster flash talks

17:15 - 18:30 Session 3: Concurrent sessions

Session 3A: Biomarkers/diagnostics with therapeutic impact

Chair: K Döhner (Germany)

• Biomarker-guided precision medicine in leukemia
  K Döhner (Germany)
• Discovering predictive precision therapy biomarkers from multi-omic data
  E Ruppin (United States)
• Short talk (selected from abstract submissions)

Session 3B: Data Sharing/harmonization

Chair: A Culhane (Ireland)

• Multi-omic data harmonization
  A Culhane (Ireland)
• Data infrastructure
  S Volchenboum (United States)
• The Danish Lymphoid-lineage Cancer Research (DALY-CARE) resource – an example cohort of +65000 patients with +3000 routine data variables per patient for development of data-driven hematology
  C Niemann (Denmark)

Session 3C: Addressing intra-patient heterogeneity in diagnosis, treatment and disease monitoring

Chair: T Zenz (Switzerland)

• Modelling and targeting intra-patient heterogeneity in pediatric cancers
  K Karlsson (Sweden)
• Targeting heterogeneity in CLL
  T Zenz (Switzerland)
• Short talk (selected from abstract submissions)

18:30 - 19:30 Welcome reception + Poster session

08:30 - 09:45 Session 4: Next generation approaches to precision medicine

Chair: I Oehme (Germany)

• Identifying precision apoptosis in solid and hematological cancers
  A Letai (United States)
• The pediatric drug sensitivity profiling
  I Oehme (Germany)
• Short talk (selected from abstract submissions)

09:45 - 10:15 Session 5: Poster flash talks 2

10:15 - 10:45 Coffee break

10:45 - 12:15 Session 6: Breakout sessions (simultaneous)

• Session 6A: Trial design, n-of-1
  Leader: P Staber (Austria)
• Session 6B: Technologies
  Leader: J Montero (Spain)
• Session 6C: Computational approaches to PM
  Leader: J Tang (Finland)

12:15 - 13:45 Lunch break

• 12:45 - 13:45 Satellite Symposium slot

13:45 - 14:30 Keynote lecture

• Speaker TBC

14:30 - 15:00 Session 7: Poster flash talks 3

15:15 - 16:30 Session 8: Concurrent sessions (simultaneous)

Session 8A: Precision medicine in the context of rare and ultra-rare tumors

Chair: B Bornhauser (Switzerland)

• Precision medicine in childhood leukemia
  B Bornhauser (Switzerland)
• Precision medicine in rare solid tumors
  A Soragni (United States)
• Title to be announced
  E Szegezdi (Ireland)

Session 8B: Identification of combination therapies

Chair: A Jeyasekharan (Singapore)

• Predicting combination therapies in lymphoma
  A Jeyasekharan (Singapore)
• From single cell analyses to effective drug combinations in solid and hematological cancers
  T Aittokallio (Finland/Norway)
• Short talk (selected from abstract submissions)

Session 8C: Next-generation genomic precision medicine

Chair: A Eisfeld (United States)

• Next gen genomic precision medicine in AML
  A Eisfeld (United States)
• Next gen genomic precision medicine in solid tumors
  J Sicklick (United States)
• Short talk (selected from abstract submissions)

16:30 - 17:00 Coffee break

17:00 - 18:30 Breakout sessions (simultaneous)

• Session 9A: Regulatory: Approval processes, reimbursement, diagnostics
  Leader: K Ligon (United States)
• Session 9B: Visibility & education
  Leader to be announced
• Session 9C: Data management, sharing, tools, Data standardization
  Leader: C Heckman (Finland)

09:00 - 10:30 Session 10: Breakout sessions (simultaneous)

• Session 10A: How should a tumor board operate? - From assay result to recommendation
  Leader: J-P Bourquin (Switzerland)
• Session 10B: Outreach to patients and patient advocates
  Leader: N Scobie (Switzerland)
• Session 10C - Shipping / storage / quality control
  Leader: T Pemovska (Austria)

10:30 - 11:00 Coffee break

11:00 - 12:15 Session 11: Concurrent sessions (simultaneous)

Session 11A: Immunotherapy - predicting responses

Chair: S Rutella (United Kingdom)

• Patient-derived non-Hodgkin lymphoma tumoroids: A tool for precision medicine
  P Perez-Galan (Spain)
• Predicting responses to immunotherapies in hematological cancers
  S Rutella (United Kingdom)
• Short talk (selected from abstract submissions)

Session 11B: Models for functional precision medicine

Chair: C Scott (Australia)

• Using organoid models to guide therapy
  C Kuo (United States)
• Translating studies from preclinical models of rare gynecological cancers
  C Scott (Australia)
• Short talk (selected from abstract submissions)

Session 11C: Measurable residual disease monitoring

Chair: M Brüggemann (Germany)

• MRD flow/pcr leukemias
  M Brüggemann (Germany)
• Functional Precision Medicine
  D Azzam (United States)
• Short talk (selected from abstract submissions)

12:15 - 13:45 Lunch break

• 12:45 - 13:45 Satellite symposium slot

13:45 - 15:00 Session 12: AI for precision medicine

Chair: S McWeeney (United States)

• AI in genomic analyses of hematological cancers
  S McWeeney (United States)
• Rapid ex vivo biosensor cultures to assess dependencies in gastroesophageal cancer​
  J Boehm (United States)
• Short talk (selected from abstract submissions)

15:00 - 15:45 Keynote lecture

• Visions and application of systems precision medicine
  O Kallioniemi (Sweden)

15:45 - 16:00 Closing